Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

David Wyles to Protease Inhibitors

This is a "connection" page, showing publications David Wyles has written about Protease Inhibitors.

 
Connection Strength
 
 
 
1.410
 
  1. Wyles DL, Schooley RT. Rong's numbers: accelerating progress in HCV therapeutic research. Sci Transl Med. 2010 May 26; 2(33):33ps25.
    View in: PubMed
    Score: 0.322
  2. Wyles DL, Kaihara KA, Schooley RT. Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors. Antimicrob Agents Chemother. 2008 May; 52(5):1862-4.
    View in: PubMed
    Score: 0.277
  3. Wyles DL, Kaihara KA, Vaida F, Schooley RT. Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets. J Virol. 2007 Mar; 81(6):3005-8.
    View in: PubMed
    Score: 0.254
  4. Wyles DL. Regimens for Patients Coinfected with Human Immunodeficiency Virus. Clin Liver Dis. 2015 Nov; 19(4):689-706, vi-vii.
    View in: PubMed
    Score: 0.116
  5. Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis. 2013 Mar; 207 Suppl 1:S33-9.
    View in: PubMed
    Score: 0.098
  6. Wyles DL. Hepatitis C virus drug resistance: implications for clinical management. Infect Dis Clin North Am. 2012 Dec; 26(4):967-78.
    View in: PubMed
    Score: 0.096
  7. Wyles DL. Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection. Top HIV Med. 2010 Oct-Nov; 18(4):132-6.
    View in: PubMed
    Score: 0.083
  8. Gr?nberger C, Wyles DL, Kaihara KA, Schooley RT. 3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication. J Infect Dis. 2008 Jan 01; 197(1):42-5.
    View in: PubMed
    Score: 0.068
  9. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis. 2005 Jan 01; 40(1):174-81.
    View in: PubMed
    Score: 0.055
  10. Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Blum J, Wyles DL, Rowan SE, Ibrahim ME, Zheng JH, Johnson B, Gomez J, Choi YJ, Cendali F, Haas H, Roon L, Bushman LR, Anderson PL, Kiser JJ. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. J Antimicrob Chemother. 2020 11 01; 75(11):3303-3310.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)